Coherus Oncology, Inc. (NASDAQ:CHRS) Financial Performance Analysis

Coherus Oncology, Inc. (NASDAQ:CHRS) has a negative ROIC of -153.12%, indicating inefficiencies in capital utilization compared to its peers.Atara Biotherapeutics (NASDAQ:ATRA) showcases a strong financial position with a ROIC of 222.66% and a WACC of 5.98%, highlighting its efficiency in capital utilization.The comparison of ROIC and WACC among peers emphasizes the importance of these metrics in assessing a company's financial health, with Coherus needing significant improvement.Coherus Oncology, Inc. (NAS ...